Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk (IATROPREV)

Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk.

The IATROPREV project is an organizational innovation experimentation project, carried out in Hauts-de-France by the University hospitals of Amiens and Lille, the ARS and the URPS Doctors and Pharmacists of Hauts-de-France and following to the social security financing law of 2018, allowing experimentation with new organizations in the health sector, according to article 51. The objectives of this course are to improve the relevance of prescription in elderly people with multiple drugs as well as, the coordination of care between the city and the hospital through the sharing of information and the establishment of multi-professional consultations between the various care actors.

Study Overview

• Status: Recruiting
• Conditions: Consultation; Follow-up; Iatrogenic Effect; Prescription

• Study Type: Observational
• Enrollment (Anticipated): 1500

Contacts and Locations

• Study Contact: Name: Frédéric BLOCH, MD; Phone Number: 03 22 45 57 20; Email: bloch.frederic@chu-amiens.fr

Study Locations

• France
  • Amiens, France, 80054
    • Recruiting
    • Amiens University Hospital
    • Contact: Frédéric BLOCH, MD; Phone Number: 03 22 45 57 20; Email: bloch.frederic@chu-amiens.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

patient hospitalized in the geriatric medicine department with olymedicated drugs

Description

Inclusion Criteria:

• patient hospitalized in the geriatric medicine department
• Potential involvement of a drug in hospitalization or potential or proven iatrogenic event during hospitalization;
• Numerous therapeutic modifications (3 or more);
• Drug interaction or introction of a new drug with one or more drug interactions;
• Medicinal product with a narrow therapeutic marge drug requiring close monitoring.

Exclusion Criteria:

• patient non hospitalized in the geriatric medicine department

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of side effect number in ederly with polymedicated drugs	Change of side effect number in ederly with polymedicated drugs	up to 4 years

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire, Amiens

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 1, 2021
• Primary Completion (ANTICIPATED): September 1, 2025
• Study Completion (ANTICIPATED): September 1, 2025

Study Registration Dates

• First Submitted: September 7, 2021
• First Submitted That Met QC Criteria: September 7, 2021
• First Posted (ACTUAL): September 16, 2021

Study Record Updates

• Last Update Posted (ACTUAL): February 8, 2023
• Last Update Submitted That Met QC Criteria: February 7, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Keywords: consultation; follow-up; iatrogenic; prescription
• Other Study ID Numbers: PI2021_843_0158

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No